
Incyte (INCY) Stock Forecast & Price Target
Incyte (INCY) Analyst Ratings
Bulls say
Incyte is a pharmaceutical company with a strong focus on developing small-molecule drugs. Their leading drug, Jakafi, is partnered with Novartis and treats rare blood cancers and graft versus host disease. Incyte also has a diverse portfolio of other marketed drugs and a promising pipeline in both oncology and dermatology. Despite risks such as slow market uptake and delays in approvals, their strong financials, experienced leadership team, and potential recurring benefit from Opzelura give us a positive outlook on the company's stock.
Bears say
Incyte is facing challenges and potential risks with their lead drug, Jakafi, approaching the end of its exclusivity in 2027 and facing competition from new and upcoming treatments. The company's pipeline is heavily focused on oncology and dermatology, which may limit their growth potential in other therapeutic areas. The positive CHMP opinion for their latest dermatology drug, Opzelura, may provide some growth opportunities in Europe, but it will take time to catch up to the US market. However, the company's valuation is high with an EV of ~$28B and a 12-month price objective of $140 per share, and any failures in their ongoing clinical programs could significantly impact their future revenue and financial success.
This aggregate rating is based on analysts' research of Incyte and is not a guaranteed prediction by Public.com or investment advice.
Incyte (INCY) Analyst Forecast & Price Prediction
Start investing in Incyte (INCY)
Order type
Buy in
Order amount
Est. shares
0 shares